Headlines about Cyclacel Pharmaceuticals (NASDAQ:CYCC) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cyclacel Pharmaceuticals earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.7004212131847 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Cyclacel Pharmaceuticals traded up $0.01, hitting $1.45, during trading hours on Thursday, according to Marketbeat.com. The company had a trading volume of 1,000 shares, compared to its average volume of 55,157. Cyclacel Pharmaceuticals has a one year low of $1.28 and a one year high of $4.56.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings results on Monday, May 14th. The biotechnology company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.01. research analysts expect that Cyclacel Pharmaceuticals will post -0.43 earnings per share for the current year.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.